Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
*End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June..
*End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June..
Roivant Sciences Ltd ROIV and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its..